Related Experiment Video
Updated: Jul 18, 2026
09:22
Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet
Published on: November 4, 2015
Chronic thromboembolic pulmonary hypertension
Franco Piovella1, Andrea M D'Armini, Marisa Barone
1IRCCS Policlinico San Matteo, Pavia, Italy. f.piovella@smatteo.pv.it
Seminars in Thrombosis and Hemostasis
|December 16, 2006
Summary
Pulmonary endarterectomy (PEA) offers a life-saving treatment for chronic thromboembolic pulmonary hypertension (CTEPH). This surgical intervention significantly improves pulmonary artery pressure and patient survival rates, even in severe cases.
Area of Science:
- Cardiology
- Pulmonary Medicine
- Surgical Innovation
Background:
- Chronic thromboembolic pulmonary hypertension (CTEPH) arises from unresolved pulmonary emboli, leading to increased pulmonary vascular resistance.
- CTEPH is a progressive, lethal condition with no effective medical therapies; pulmonary endarterectomy (PEA) is the primary treatment.
- A multidisciplinary program was established to enhance expertise in managing CTEPH patients undergoing PEA.
Purpose of the Study:
- To evaluate the outcomes of a specialized pulmonary endarterectomy (PEA) program for chronic thromboembolic pulmonary hypertension (CTEPH).
- To assess the long-term efficacy and safety of PEA in improving hemodynamics and survival in CTEPH patients.
Main Methods:
- A retrospective analysis of 134 pulmonary endarterectomy (PEA) procedures performed between 1994 and the study's conclusion.
- Preoperative and postoperative assessment of New York Heart Association (NYHA) functional class, mean pulmonary artery pressure, and pulmonary vascular resistance.
- Evaluation of operative mortality and long-term survival rates, including hemodynamic and functional status at follow-up.
Main Results:
- Preoperatively, patients presented with severe pulmonary hypertension (mean PAP 47 mmHg, PVR 1149 dyn/s/cm(-5)) and advanced NYHA class (75% Class IV).
- Overall operative mortality was 9.7%, reduced to 4.5% by 2004. Three-year survival was 83.3%, stable up to 10 years.
- Post-PEA, significant improvements were observed: mean PAP decreased to 25 mmHg, PVR to 322 dyn/s/cm(-5), and 94% of patients achieved NYHA Class I or II at 3-year follow-up.
Conclusions:
- Pulmonary endarterectomy (PEA) is a highly effective treatment for chronic thromboembolic pulmonary hypertension (CTEPH), significantly improving hemodynamics and long-term survival.
- A dedicated multidisciplinary program enhances the success of PEA, leading to sustained functional recovery and improved quality of life for CTEPH patients.
- PEA offers a durable solution for CTEPH, with patients remaining in improved functional classes and requiring only oral anticoagulation post-surgery.
Related Concept Videos
01:19Pulmonary Embolism I: Introduction
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
01:29Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
01:19Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...
01:30Pulmonary Hypertension: Classification and Pathogenesis
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:23Chronic Obstructive Pulmonary Disease I: Introduction
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...